Assessing time to pulmonary function benefit following antibiotic treatment of acute cystic fibrosis exacerbations (Q34221582)

31 July 2017

Assessing time to pulmonary function benefit following antibiotic treatment of acute cystic fibrosis exacerbations (English)

1 reference

31 July 2017

0 references

Donald R VanDevanter

1

1 reference

31 July 2017

Mary A O'Riordan

series ordinal

2

1 reference

31 July 2017

Jeffrey L Blumer

series ordinal

3

1 reference

31 July 2017

Michael W Konstan

series ordinal

4

1 reference

31 July 2017

6 October 2010

1 reference

31 July 2017

1 reference

31 July 2017

11

1 reference

31 July 2017

137

1 reference

https://scigraph.springernature.com/pub.10.1186/1465-9921-11-137

31 July 2017

0 references

cites work

Location and duration of treatment of cystic fibrosis respiratory exacerbations do not affect outcomes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2959026

Healthcare expenditures for privately insured people with cystic fibrosis

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2959026

Cystic fibrosis pulmonary guidelines: treatment of pulmonary exacerbations

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2959026

Duration of intravenous antibiotic therapy in people with cystic fibrosis

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2959026

Cystic fibrosis pulmonary exacerbations

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2959026

Management of pulmonary disease in patients with cystic fibrosis

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2959026

The efficacy and safety of meropenem and tobramycin vs ceftazidime and tobramycin in the treatment of acute pulmonary exacerbations in patients with cystic fibrosis

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2959026

Susceptibility testing of Pseudomonas aeruginosa isolates and clinical response to parenteral antibiotic administration: lack of association in cystic fibrosis

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2959026

Reduction of sputum Pseudomonas aeruginosa density by antibiotics improves lung function in cystic fibrosis more than do bronchodilators and chest physiotherapy alone

28 October 2018

1 reference

12 December 2020

Randomized trial of ceftazidime versus placebo in the management of acute respiratory exacerbations in patients with cystic fibrosis

1 reference

12 December 2020

Acute pulmonary exacerbations in cystic fibrosis. A double-blind trial of tobramycin and placebo therapy

1 reference

12 December 2020

Pulmonary exacerbations in cystic fibrosis

1 reference

12 December 2020

Return of FEV1 after pulmonary exacerbation in children with cystic fibrosis

1 reference

12 December 2020

Identifiers

DOI

10.1186/1465-9921-11-137

1 reference

Dimensions Publication ID

31 July 2017

0 references

1 reference

31 July 2017

1 reference